XTL Biopharmaceuticals Ltd XTLB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren’s syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 4
- Website
- https://www.xtlbio.com
Valuation
|
Metric
|
XTLB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.64 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
XTLB
Financial Strength
|
Metric
|
XTLB
|
|---|---|
Quick Ratio | 11.16 |
Current Ratio | 11.43 |
Interest Coverage | — |
Quick Ratio
XTLB
Profitability
|
Metric
|
XTLB
|
|---|---|
Return on Assets (Normalized) | −23.80% |
Return on Equity (Normalized) | −25.60% |
Return on Invested Capital (Normalized) | −27.41% |
Return on Assets
XTLB
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Fxbbmbvls | Xqqkj | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Lxwwydzn | Sjxkgf | $115.9 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Gzccrsrw | Tyglfy | $109.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Ckcymffy | Plxndg | $34.2 Bil | |||
| argenx SE ADR
ARGX
| Wwdwvfds | Ypghc | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Mjxghhgt | Thw | $29.2 Bil | |||
| Moderna Inc
MRNA
| Lxzhbbc | Ddp | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Tvhjgjzqh | Plch | $15.6 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Ftnmhnpf | Kgcjgd | $13.1 Bil | |||
| Incyte Corp
INCY
| Ttzjsrmfb | Bhsmll | $12.7 Bil |
United States